search
Back to results

Percutaneous Coronary Intervention Versus Medical Treatment for Stable Angina Pectoris (DANANGINA)

Primary Purpose

Coronary Heart Disease, Stable Angina, Ischemic Heart Disease

Status
Unknown status
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
Percutaneous Coronary Intervention
Sham-percutaneous coronary intervention
Sponsored by
Herlev and Gentofte Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Coronary Heart Disease focused on measuring Atherosclerosis, Fractional flow reserve, Optimal medical therapy, Antianginal, Percutaneous Coronary Intervention

Eligibility Criteria

18 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria

  • Age 18-85 years
  • Patients with stable angina pectoris undergoing elective coronary angiography
  • Canadian Cardiovascular Society (CCS) class 2 or 3
  • Informed consent
  • Lesions in one or more coronary vessels with a diameter >2.5 mm with FFR-values ≤0.80, and suitable for complete revascularization with PCI.

Exclusion criteria

  • Contraindication to PCI or dual antiplatelet therapy (DAPT)
  • Use of or indication for oral anticoagulants (OAC) or novel oral anticoagulants (NOAC)
  • Use of clopidogrel
  • Life expectancy of less than 2 years
  • Severe valvular disease
  • Severe comorbidity
  • Acute coronary event within the past 12 months
  • Left ventricular ejection fraction ≤35%.
  • Renal function with estimated glomerular filtration rate (eGFR) <30 mL/min
  • Pregnant or nursing
  • Severe coronary artery disease (left main stenosis, 3-vessel disease, proximal left anterior descending stenosis, chronic total occlusion of major vessel)
  • Coronary disease where complete revascularization by PCI is considered difficult or impossible.

Sites / Locations

  • Gentofte University HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Percutaneous Coronary Intervention

Sham-percutaneous coronary intervention

Arm Description

Conventional PCI and optimal medical therapy

Sham-PCI and optimal medical therapy

Outcomes

Primary Outcome Measures

Combined endpoint of strategy success
Number of patients without angina (freedom from angina) and without hospital admission for intolerable stable angina pectoris, unstable angina pectoris, or acute myocardial infarction

Secondary Outcome Measures

Number of all-cause death, any myocardial infarction, stroke, major bleeding, and severe drug reaction
see above
Number of conversions to PCI for procedural complication (sham-PCI group)
see above
Number of patients with hospital admission for intolerable stable angina, unstable angina pectoris, or acute myocardial infarction
see above
Number of patients in CCS class 1, 2, and 3, respectively, without hospital admission for intolerable stable angina, unstable angina pectoris, or acute myocardial infarction
see above
Number of patients with clinically driven coronary revascularization
see above
Change in CCS class
see above
Use of antianginal agents
0, 1, 2, or 3 agents
Quality of life score
5- level EQ-5D (EQ-5D-5L) questionnaire. Each dimension will be scored from 0-5 where a higher score means a better outcome. .
Change in angina-specific quality of life
Seattle Angina Questionnaire 7. Values will range from 0-100 where higher score means better outcome.
Primary composite endpoint in the modified intention-to-treat population
The modified intention-to-treat population is comprised of patients who underwent the study procedure and follow-up without overt or formal unblinding.
Change in CCS class in the modified intention-to-treat population
The modified intention-to-treat population is comprised of patients who underwent the study procedure and follow-up without overt or formal unblinding.
Change in Seattle Angina Questionnaire 7 score in the modified intention-to-treat population
The modified intention-to-treat population is comprised of patients who underwent the study procedure and follow-up without overt or formal unblinding. Values will range from 0-100 where higher score means better outcome.
Change in generic quality of life (EQ-5D-5L) in the modified intention-to-treat population
The modified intention-to-treat population is comprised of patients who underwent the study procedure and follow-up without overt or formal unblinding. Each dimension will be scored from 0-5 where a higher score means a better outcome.

Full Information

First Posted
June 15, 2020
Last Updated
July 29, 2020
Sponsor
Herlev and Gentofte Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT04496648
Brief Title
Percutaneous Coronary Intervention Versus Medical Treatment for Stable Angina Pectoris
Acronym
DANANGINA
Official Title
The Danish Randomized Sham-Controlled Study of Invasive Versus Medical Treatment for Stable Angina Pectoris
Study Type
Interventional

2. Study Status

Record Verification Date
July 2020
Overall Recruitment Status
Unknown status
Study Start Date
June 15, 2020 (Actual)
Primary Completion Date
May 31, 2022 (Anticipated)
Study Completion Date
September 30, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Herlev and Gentofte Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Patients with ischemic heart disease and symptoms due to lack of oxygen to the heart on exertion (stable angina pectoris) are usually treated by either percutaneous coronary intervention (PCI) or optimal medical therapy (OMT) alone. In patients with mild to moderate coronary artery disease the prognostic impact of PCI is probably limited. Furthermore it is unclear which treatment is superior in terms of relieving symptoms (PCI or OMT). In this trial, patients with mild to moderate coronary artery disease will be randomized to PCI or sham-PCI. All patients will undergo optimal medical therapy. It is hypothesized that PCI is superior to sham-PCI in patients with stable angina pectoris undergoing optimal medical therapy in terms of symptom-relief.
Detailed Description
Ischemic heart disease (IHD) is a major cause of death and disability worldwide. Patients with ischemic heart disease and symptoms due to lack of oxygen to the heart on exertion (stable angina pectoris) are usually treated by either percutaneous coronary intervention (PCI) or optimal medical therapy (OMT) alone. In patients with mild to moderate coronary artery disease the prognostic impact of PCI is probably limited. Furthermore it is unclear which treatment is superior in terms of relieving symptoms (PCI or OMT). Both treatments are effective in terms of reducing symptoms, but come with potential side effects. PCI has in previous trials failed to show superiority compared to medical therapy in patients with stable angina pectoris. However, many visually significant lesions do not limit the blood flow significantly to the heart, and stenting such a lesion only exposes the patient to the risk of side effects of intervention. In recent years it has therefore become guideline-recommended practice to perform physiological test to evaluate a potential stenosis. During an angiography this is most often done using fractional flow reserve (FFR). This study tests the optimal strategy for treatment of angina-symptoms in patients with stable pectoris. PCI is performed with modern stent designs and use of intravascular functional testing (FFR-guided PCI) and compared to sham-PCI.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coronary Heart Disease, Stable Angina, Ischemic Heart Disease
Keywords
Atherosclerosis, Fractional flow reserve, Optimal medical therapy, Antianginal, Percutaneous Coronary Intervention

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Randomized patient-blind sham-controlled trial
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
450 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Percutaneous Coronary Intervention
Arm Type
Active Comparator
Arm Description
Conventional PCI and optimal medical therapy
Arm Title
Sham-percutaneous coronary intervention
Arm Type
Placebo Comparator
Arm Description
Sham-PCI and optimal medical therapy
Intervention Type
Procedure
Intervention Name(s)
Percutaneous Coronary Intervention
Other Intervention Name(s)
PCI
Intervention Description
Percutaneous coronary intervention with drug-eluting stents and modern techniques
Intervention Type
Procedure
Intervention Name(s)
Sham-percutaneous coronary intervention
Other Intervention Name(s)
sham-PCI
Intervention Description
Sham-PCI procedure for at least 15 minutes that includes shifting the C-arm, reinserting the FFR-wire in the catheter and inflating the device.
Primary Outcome Measure Information:
Title
Combined endpoint of strategy success
Description
Number of patients without angina (freedom from angina) and without hospital admission for intolerable stable angina pectoris, unstable angina pectoris, or acute myocardial infarction
Time Frame
3 months
Secondary Outcome Measure Information:
Title
Number of all-cause death, any myocardial infarction, stroke, major bleeding, and severe drug reaction
Description
see above
Time Frame
3 months
Title
Number of conversions to PCI for procedural complication (sham-PCI group)
Description
see above
Time Frame
3 months
Title
Number of patients with hospital admission for intolerable stable angina, unstable angina pectoris, or acute myocardial infarction
Description
see above
Time Frame
3 months
Title
Number of patients in CCS class 1, 2, and 3, respectively, without hospital admission for intolerable stable angina, unstable angina pectoris, or acute myocardial infarction
Description
see above
Time Frame
3 months
Title
Number of patients with clinically driven coronary revascularization
Description
see above
Time Frame
3 months
Title
Change in CCS class
Description
see above
Time Frame
3 months
Title
Use of antianginal agents
Description
0, 1, 2, or 3 agents
Time Frame
3 months
Title
Quality of life score
Description
5- level EQ-5D (EQ-5D-5L) questionnaire. Each dimension will be scored from 0-5 where a higher score means a better outcome. .
Time Frame
3 months
Title
Change in angina-specific quality of life
Description
Seattle Angina Questionnaire 7. Values will range from 0-100 where higher score means better outcome.
Time Frame
3 months
Title
Primary composite endpoint in the modified intention-to-treat population
Description
The modified intention-to-treat population is comprised of patients who underwent the study procedure and follow-up without overt or formal unblinding.
Time Frame
3 months
Title
Change in CCS class in the modified intention-to-treat population
Description
The modified intention-to-treat population is comprised of patients who underwent the study procedure and follow-up without overt or formal unblinding.
Time Frame
3 months
Title
Change in Seattle Angina Questionnaire 7 score in the modified intention-to-treat population
Description
The modified intention-to-treat population is comprised of patients who underwent the study procedure and follow-up without overt or formal unblinding. Values will range from 0-100 where higher score means better outcome.
Time Frame
3 months
Title
Change in generic quality of life (EQ-5D-5L) in the modified intention-to-treat population
Description
The modified intention-to-treat population is comprised of patients who underwent the study procedure and follow-up without overt or formal unblinding. Each dimension will be scored from 0-5 where a higher score means a better outcome.
Time Frame
3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria Age 18-85 years Patients with stable angina pectoris undergoing elective coronary angiography Canadian Cardiovascular Society (CCS) class 2 or 3 Informed consent Lesions in one or more coronary vessels with a diameter >2.5 mm with FFR-values ≤0.80, and suitable for complete revascularization with PCI. Exclusion criteria Contraindication to PCI or dual antiplatelet therapy (DAPT) Use of or indication for oral anticoagulants (OAC) or novel oral anticoagulants (NOAC) Use of clopidogrel Life expectancy of less than 2 years Severe valvular disease Severe comorbidity Acute coronary event within the past 12 months Left ventricular ejection fraction ≤35%. Renal function with estimated glomerular filtration rate (eGFR) <30 mL/min Pregnant or nursing Severe coronary artery disease (left main stenosis, 3-vessel disease, proximal left anterior descending stenosis, chronic total occlusion of major vessel) Coronary disease where complete revascularization by PCI is considered difficult or impossible.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Sune Ammentorp Haahr-Pedersen, MD
Phone
+45 38672267
Ext
+4530220889
Email
sunped01@regionh.dk
First Name & Middle Initial & Last Name or Official Title & Degree
Niels Thue Olsen, MD, PhD
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ole Havndrup
Organizational Affiliation
Zealand Unviersity Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Ole Ahlehoff
Organizational Affiliation
Odense University Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Ashkan Eftekhari
Organizational Affiliation
Aarhus University Hospital Skejby
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Martin Kirk
Organizational Affiliation
Aalborg University Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Rikke Sørensen
Organizational Affiliation
Rigshospitalet, Denmark
Official's Role
Principal Investigator
Facility Information:
Facility Name
Gentofte University Hospital
City
Gentofte
State/Province
Copenhagen
ZIP/Postal Code
2900
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Niels Thue Olsen, MD, PhD
Phone
+45 38 67 25 60
Email
niels.thue.olsen@regionh.dk

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Data will be shared upon request.
IPD Sharing Time Frame
1 year after publication
IPD Sharing Access Criteria
Upon request

Learn more about this trial

Percutaneous Coronary Intervention Versus Medical Treatment for Stable Angina Pectoris

We'll reach out to this number within 24 hrs